Joshua Faust

DLK1 is a GATA1s-driven dependency and therapeutic target in Down syndrome–associated myeloid leukemia; Blood Advances; (2026).

Mesothelin promotes acute myeloid leukemia progression through LYN-dependent signaling.; The Journal of biological chemistry; (2026).

Dual targeting of tumoral cells and immune microenvironment by blocking the IL-33/IL1RL1 pathway; Nature Communications; (2025).

Mechanism of acquired resistance to histone deacetylase inhibitor, romidepsin, in myeloid leukemia associated with down syndrome; Blood; (2025).

Mesothelin: An Immunotherapeutic Target beyond Solid Tumors; Cancers; (2022).